SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing extreme volatility and high trading volume as investors brace for the upcoming FDA advisory committee meeting regarding the approval of its DMD therapy. The community remains deeply divided, with bulls pointing to positive trial results and community support, while bears focus on regulatory hurdles, statistical methodology debates, and significant price swings ahead of the binary decision.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors grapple with a significant valuation decline following its IPO and ongoing concerns about potential downward pressure from upcoming share lockup expirations. Community sentiment remains deeply polarized, with bulls viewing recent technical milestones as a foundation for long-term growth, while skeptics emphasize lack of profitability and the risk of massive dilution as insider shares hit the market.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is facing significant volatility as investors debate the companys heavy capital expenditure plans, despite reporting its strongest quarterly revenue growth in over fifteen years. The community is actively debating whether this sell-off is a calculated shakeout driven by market maker manipulation and short-selling or a fundamental reassessment of AI infrastructure spending returns.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is at the center of investor focus following massive multibillion-dollar infrastructure partnerships with SK Group and reported financing discussions for OpenAI's data center projects. While these developments highlight NVIDIA's deep integration into global AI expansion, community sentiment remains split between bullish optimism regarding long-term growth and skepticism over the financial sustainability of these large-scale circular investments.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing intense activity driven by a wave of bullish analyst price target hikes following its 'Advancing AI' event, which highlighted a robust roadmap for its next-gen chips. Despite this optimism, the stock is experiencing significant volatility as the community remains sharply divided between investors betting on long-term AI infrastructure growth and traders aggressively shorting the stock amid fears of a broader sector bubble.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing intense volatility driven by broader semiconductor sector rotation, fears regarding Chinese NAND competition, and aggressive short-selling. While traders are actively debating the sustainability of the memory cycle and recent price retracements, many in the community view the current sell-off as a temporary shakeout that ignores strong fundamental cash flows ahead of upcoming earnings and investor updates.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to a new government grant and a high-profile move to the Nasdaq exchange, even as the stock experiences broader volatility common among high-beta tech plays. Community discussions are split between those highlighting the company's enterprise momentum with partners like AT&T and those debating whether valuation concerns or macro-driven rotation are responsible for the recent price swings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility driven by speculation around geopolitical tensions in the Middle East and ongoing debates over the sustainability of massive AI-related capital expenditures. The community remains deeply divided, with traders actively debating the validity of recent market bounces against fears of a deepening correction and potential macroeconomic policy shifts.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors grapple with massive AI infrastructure spending plans from tech giants and mounting geopolitical tensions in the Middle East. The community remains deeply divided, with some traders viewing the current price weakness as a prime opportunity to buy the dip while others fear that the AI-driven sector is in a bubble prone to further downside.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to a significant jump in liquefaction fees and heightened geopolitical tensions in the Strait of Hormuz that continue to disrupt global LNG supplies. The community is actively debating the company's valuation, upcoming earnings catalysts, and the potential impact of sustained commodity price spreads on long-term profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MetaVia (Nasdaq: $MTVA ) presents its dual-agonist obesity candidate DA-1726 and MASH program at the Life Sciences Virtual Investor Forum on June 24 at 10:30 AM ET. 
 
MetaVia Inc. (Nasdaq: MTVA) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 10:30 AM ET on Wednesday, June 24, 2026. 
 
The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum 
 
To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5394654/metavia-inc-nasdaq-mtva?utm_source=b2i&amp;utm_medium=marketing&amp;utm_campaign=0624LifeSciencesForumVIC 
 
Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 
 
HH Kim, CEO and President, presents for MetaVia, alongside CFO Marshall H. Woodworth. Kim previously served as General Counsel and Senior Vice President of Dong-A ST and Dong-A Socio Group, while Woodworth brings more than 35 years in financial roles, including over 20 years across life sciences and related sectors. 
 
MetaVia is a clinical-stage biotechnology company focused on cardiometabolic diseases. Its lead candidate, DA-1726, is a novel oxyntomodulin analogue functioning as a dual GLP-1 and glucagon receptor agonist in development for obesity, which demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction in a Phase 1 trial. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, for metabolic dysfunction-associated steatohepatitis (MASH). 
 
Learn more at https://ir.metaviatx.com/. 
 
Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. 
 
B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

top moon

이길수경마tv

David Shapiro

Dwight

Edward

Alfredo

Bonnie Siegmund

Ariana Storck

Craig Salinas

Eugene Davenport

Michael Musto

Roberta Creech

Henry Callaghan

John Park

Melissa Vermillion

Shirley Hall

Micheal Fikes

James Adair

Jeanne Hodges

Kelly Distaffen

Nina Studdard

Renee Blankenship

Filomena Marsh

Raymond Oliver

Lucy Pena

Terry Skora

Amber Reilly

Edwina Packard

Karen Paris

Lillian Ellis

StockTwits Web

MetaVia Inc.

 ) presents its dual-agonist obesity candidate DA-1726 and MASH program at the Life Sciences Virtual Investor Forum on June 24 at 10:30 AM ET. 
 
MetaVia Inc. (Nasdaq: MTVA) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 10:30 AM ET on Wednesday, June 24, 2026. 
 
The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: 

 
 
To register and view the presentation: 

 
 
HH Kim, CEO and President, presents for MetaVia, alongside CFO Marshall H. Woodworth. Kim previously served as General Counsel and Senior Vice President of Dong-A ST and Dong-A Socio Group, while Woodworth brings more than 35 years in financial roles, including over 20 years across life sciences and related sectors. 
 
MetaVia is a clinical-stage biotechnology company focused on cardiometabolic diseases. Its lead candidate, DA-1726, is a novel oxyntomodulin analogue functioning as a dual GLP-1 and glucagon receptor agonist in development for obesity, which demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction in a Phase 1 trial. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, for metabolic dysfunction-associated steatohepatitis (MASH). 
 
Learn more at 

. 
 
Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.

. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at 

. 
 
B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

MetaVia Inc. will highlight its obesity and MASH pipeline at the Life Sciences Virtual Investor Forum, including DA-1726, a dual GLP-1 and glucagon receptor agonist showing promising Phase 1 weight-loss data. 
 
Learn more about the Featured Conference at: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

Explore the Life Sciences Virtual Investor Forum by Virtual Investor Conferences, featuring online presentations from public life science companies for global retail and institutional investors.

B2idigital

VIC Life Sciences Virtual Investor Forum | B2i Digital Featured Conference

MetaVia Inc. will highlight its obesity and MASH pipeline at the Life Sciences Virtual Investor Forum, including DA-1726, a dual GLP-1 and glucagon receptor agonist showing promising Phase 1 weight-loss data. 
 
Learn more about the Featured Conference at: 